Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,585.35
(
-0.59%
)
US TECH 100
23,612.20
(
-0.77%
)
Dow Jones
45,886.97
(
-0.73%
)
Brent Oil
107.66
(
1.01%
)
Bitcoin
69,471.84
(
-2.48%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 94184

Wednesday, 04/14/2010 7:48:53 PM

Wednesday, April 14, 2010 7:48:53 PM

Post# of 257259
Agreed—the ITMN-191 efficacy results are fine; however, efficacy has never been a problem with any HCV protease inhibitor. All told, I don’t think the business rationale for ITMN-191 is materially enhanced by the (preliminary) new data.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now